Stratified assessment of clazosentan efficacy following subarachnoid hemorrhage: A multi-center cohort study.

ABSTRACT: There are conflicting results regarding the efficacy of clazosentan, a selective endothelin A receptor antagonist, on cerebral vasospasm after subarachnoid hemorrhage (SAH). As the effectiveness of clazosentan for patients over 75 years old and those with World Federation of Neurosurgical Societies grade V has not been established, we aimed to evaluate its efficacy in real-world clinical settings. This study utilized prospectively collected data from consecutive SAH patients across 4 stroke centers, comparing 187 patients treated with clazosentan to 223 patients receiving standard of care. The incidence of favorable functional outcomes (modified Rankin Scale score 0-2) at 90 days after SAH, occurred more frequently in patients receiving clazosentan (74.9% vs 65.0%, p = 0.032). Multi

SUBMITTER: Sakata H 

PROVIDER: S-EPMC12640272 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature